MESO FY 2025 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+191.4% YoY

Gross Profit

$12M70.2% margin

Operating Income

-$62M-363.1% margin

Net Income

-$102M-593.9% margin

EPS (Diluted)

$-0.84

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$51M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$785M

Total Liabilities

$187M

Stockholders' Equity

$597M

Cash & Equivalents

$161M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$6M	+191.4%
Gross Profit	$12M	-$35M	+134.3%
Operating Income	-$62M	-$84M	+25.8%
Net Income	-$102M	-$88M	-16.1%